Oral GPR142 agonists for the treatment of Diabetes
In late 2016 C4XD was awarded a ~£140k Biomedical Catalyst feasibility study award from InnovateUK to progress hits for the GPR142 agonist programme for diabetes. Type 2 diabetes (“T2D”) affects over 420 million people worldwide, creating an enormous healthcare and socio-economic burden. The GPR142 receptor has been recently reported to be a potential and exciting novel target for the treatment of T2D with several advantages. Firstly, its activation results in insulin secretion but only in the presence of high blood sugar levels, avoiding the life-threatening side effect of low blood sugar associated with insulin-based therapies. Secondly, GPR142-based medicines would be orally administered, avoiding compliance issues caused by injectable therapies. Prosecution
of this programme has gone well with several novel lead C4XD compounds showing significant activity in a pre-clinical oral glucose tolerance test.
Lilly is the leader in this area and completed a Phase 1 clinical study with its candidate during the middle of 2018 which also had an additional diabetes patient cohort as a preliminary investigation into its activity in patients. The results from this study will drive commercial interest for this programme and discussions with potential partners.